Simple and robust antibody microarray-based immunoassay platform for sensitive and selective detection of PSA and hK2 toward accurate diagnosis of prostate cancer

Sensing and Bio-Sensing Research

Volumn 3, Issue , 2015, Pages 105-111

  Lee, S W ^a   Hosokawa, K ^a   Kim, S ^b   Laurell, T ^b,c   Maeda, M ^a  

^a RIKEN   (Japan)

^b Dongguk University   (South Korea)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Antibody cross reaction; Duplex assay; Human kallikrein 2 (hK2); Microarray; Prostate specific antigen (PSA); Sandwich assay

Indexed keywords

EID: 84922978673     PISSN: None     EISSN: 22141804     Source Type: Journal    
DOI: 10.1016/j.sbsr.2015.01.003     Document Type: Article

References (38)

1. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 2008, 8:268-278.
2. Hugosson J., Aus G., Lilja H., Lodding P., Pihl C.G. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004, 100:1397-1405.
3. Andriole G.L., Levin D., Crawford E.D., Gelmann E., Pinsky P.F., Chia D., Kramer B.S., Reding D., Church T.R., Grubb R.L., Izmirlian G., Ragard L.R., Clapp J.D., Prorok P.C., Gohagan J.K. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J. Natl. Cancer Inst. 2005, 97:433-438.
4. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Scott Lucia M., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., Coltman C.A. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0ngperMilliliter. N. Engl. J. Med. 2004, 350:2239-2246.
5. Aus G., Damber J.E., Khatami A., Lilja H., Stranne J., Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level results of a prospective randomized, population-based study. Arch. Intern. Med. 2005, 165:1857-1861.
6. Vickers A., Cronin A., Roobol M., Savage C., Peltola M., Pettersson K., Scardino P.T., Schroder F., Lilja H. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J. Clin. Oncol. 2010, 28:2493-2498.
7. Strope S.A., Andriole G.L. Improving prostate-specific antigen screening. J. Clin. Oncol. 2010, 28:2491-2492.
8. Riegman P., Vliestra R.J., Suurmeijer J., Cleutjens C., Trapman J. Characterization of human kallikrein locus. Genomics 1992, 14:6-11.
9. Schedlich L.J., Bennetts B.H., Morris B.J. Primary structure of a human glandular kallikrein gene. DNA 1987, 6:429-437.
10. Pironnen T., Villoutreix B.O., Becker C., Hollingsworth K., Vihinen M., Bridon D., Qiu X., Rapp J., Dowell B., Lovgen T., Pettersson K., Lilja H. Determination and analysis of prostate specific antigen (PSA) and human glandular kallikrein 2(hK2) using synthetic peptides and computer modeling. Protein Sci. 1998, 7:259-269.
11. Becker C., Piironen T., Pettersson K., Bjork T., Wojno K.J., Oesterling J.E., Lilja H. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (hK2) in serum. J. Urol. 2000, 163:311-316.
12. Finlay J.A., Evans C.L., Day J.R., Payne J.K., Mikolajczyk S., Millar L., Kuus-Reichel K., Wolfert R., Rittenhouse H. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998, 51:804-809.
13. Kwiatkowski M., Recker F., Piironen T., Pettersson K., Otto T., Wernli M., Tscholl R. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10ng/mL. Urology 1998, 52:360-365.
14. Charlesworth M.C., Young C., Klee G., Saedi M., Mikolajczyk S., Finlay J., Tindall D. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 1997, 49:487-493.
15. Henttu P., Lukkarinen O., Vihko P. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int. J. Cancer 1990, 45:654-660.
16. van Gils M., Stenman U.H., Schalken J.A., Schröder F.H., Luider T.M., Lilja H., Bjartell A., Hamdy F.C., Pettersson K.S.I., Bischoff R., Takalo H., Nilsson O., Mulders P.F.A., Bangma C.H. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur. Urol. 2005, 48:1031-1041.
17. Haab B.B., Brown M.J., Brown P.O. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2001, 2. RESEARCH0004.
18. Jacobs J.M., Adkins J.N., Qian W., Liu T., Shen Y., Camp D.G., Smith R.D. Utilizing humanblood plasma for proteomic biomarker discovery. J. Proteome Res. 2005, 4:1073-1085.
19. Drukier A.K., Ossetrova N., Schors E., Krasik G., Grigoriev I., Koenig C., Sulkowski M., Holcman J., Brown L.R., Tomaszewski J.E., Schnall M.D., Sainsbury R., Lokshin A.E., Godovac-Zimmermann J. High-sensitivity blood-based detection of breast cancer by multi photon detection diagnostic proteomics. J. Proteome Res. 2006, 5:1906-1915.
20. MacBeath G., Schreiber S.L. Printing proteins as microarrays for high-throughput function determination. Science 2000, 289:1760-1763.
21. David D.H., Ptacek J., Snyder M. Protein microarray technology. Mech. Ageing Dev. 2007, 128:161-167.
22. Korf U., Lobke C., Sahin O., Haller F., Sultmann H., Arlt D., Poustka A. Reverse-phase protein arrays for application-oriented cancer research. Proteomics Clin. Appl. 2009, 3:1140-1150.
23. Peluso P., Wilson D.S., Do D., Tran H., Venkatasubbaiah M., Quincy D., Heidecker B., Poindexter K., Tolani N., Phelan M., Witte K., Jung L.S., Wagner P., Nock S. Optimizing antibody immobilization strategies for the construction of protein microarrays. Anal. Biochem. 2003, 312:113-124.
24. Saviranta P., Okon R., Brinker A., Warashina M., Eppinger J., Geierstanger B.H. Evaluating sandwich immunoassays in microarray format in terms of the ambient analyte regime. Clin. Chem. 2004, 50:1907-1920.
25. Kusnezow W., Jacob A., Walijew A., Diehl F., Hoheisel J.D. Antibody microarrays: an evaluation of production parameters. Proteomics 2003, 3:254-264.
26. Zhu H., Klemic J.F., Chang S., Bertone P., Casamayor A., Klemic K.G., Smith D., Gerstein M., Reed M.A., Snyner M. Analysis of yeast protein kinases using protein chips. Nat. Genet. 2000, 26:283-289.
27. Lilja H., Christensson A., Dahlén U., Matikainen M.T., Nilsson O., Pettersson K., Lövgren T. Clin. Chem. 1991, 37:1618-1625.
28. Christensson A., Laurell C., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 1990, 194:755-763.
29. Liu D., Huang X., Wang Z., Jin A., Sun X., Zhu L., Wang F., Ma Y., Niu G., Walker A., Chen X. Gold nanoparticle-based activatable probe for sensing ultralow levels of prostate-specific antigen. ACS Nano 2013, 7:5568-5576.
30. Thaxton C., Elghanian R., Thomas A., Stoeva S., Lee J., Smith N., Schaeffer A., Klocker H., Horninger W., Bartsch G., Mirkin C. Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. PNAS 2009, 106:18437-18442.
31. Rissin D.M., Kan C.W., Campbell T.G., Howes S.C., Fournier D.R, Song L., Piech T., Patel P.P., Chang L., Rivnak A.J., Ferrell E.P., Randall J.D., Provuncher G.K., Walt D.R., Duffy D.C. Nat. Biotechnol. 2010, 28:595-599.
32. Wilson D., Hanlon D., Provuncher G., Chang L., Song L., Patel P., Ferrell E., Lepor H., Partin A., Chan D., Sokoll L., Cheli C., Thiel R., Fournier D., Duffy D. Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin. Chem. 2011, 57:1712-1721.
33. Järås K., Tajudin A.A., Ressine A., Soukka T., Marko-Varga G., Bjartell A., Malm J., Laurell T., Lilja H. ENSAM: Europium Nanoparticles for Signal Enhancement of Antibody Microarrays on nanoporous silicon. J. Proteome Res. 2008, 7:1308-1314.
34. Lee S.W., Kim S., Malm J., Jeong O.C., Lilja H., Laurell T. Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibody. Anal. Chim. Acta 2013, 796:108-114.
35. Stephan C., Jung K., Nakamura T., Yousef G.M., Kristiansen G., Diamond E.P. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int. J. Urol. 2006, 13:238-243.
36. Vaisanen V., Eriksson S., Ivaska K.K., Lilja H., Nurmi M., Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin. Chem. 2004, 50:1607-1617.
37. Lilja H., Ulmert D., Bjork T., Becker C., Serio M.A., Nilsson J.A., Abrahamsson P.A., Vickers A.J., Berglund G. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50years. J. Clin. Oncol. 2007, 25:431-436.
38. Steuber T., Vickers A.J., Haese A., Becker C., Pettersson K., Chun F.K., Kattan M.W., Eastham J.A., Scardino P.T., Huland H., Lilja H. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int. J. Cancer 2006, 118:1234-1240.